{'fraction_non_alphanumeric': 0.013409961685823755, 'fraction_numerical': 0.0009578544061302681, 'mean_word_length': 5.450617283950617, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Secondary effects of hormonal contraception on the breast].

A review of the pertinent literature shows that most authors admit that oral contraception (OC) not only does not induce galactorrhea but can possibly exercise a protective effect against this dysfunction. Anatomo-pathological and epidemiological studies do not show any association between OCs and benign breast tumors; there could on the contrary be a beneficial effect linked to age of patient composition of drug and length of administration. The risk of benign tumor seems to increase among young patients with low parity on high dosages of estrogen; within the same group the risk of galactorrhea increases seven times. Contraception by progestational agents only at high doses increases the risk of benign breast tumors in postmenopausal patients with low parity. Contraception by injection of medroxyprogesterone acetate does not affect the breast; indeed mammographies taken 6 months after beginning treatment are comparable to those taken before instauration of treatment.